Dr. Shari Beth Goldfarb, MD

Dr. Goldfarb practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Goldfarb's NPI, 1750547105, was assigned on August 5, 2008. Dr. Goldfarb graduated from SUNY Upstate Medical University in 2004. Dr. Goldfarb holds New York license 242682.

Dr. Goldfarb's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Goldfarb's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Goldfarb to 5 more medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Goldfarb practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Goldfarb's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Goldfarb is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Goldfarb's licenses on file in 3 states: New York, Florida and New Jersey.

Dmand AI lists breast cancer among the conditions Dr. Goldfarb treats.

CMS data shows 298 Medicare services from Dr. Goldfarb across 4 procedure codes in 2024, for 87 Medicare patients. Medicare paid $20,194 for them. Every service was in an office.

CMS counts 87 Medicare patients who saw Dr. Goldfarb in 2024. The largest group is 65 to 74, with 48 patients. 75% of them have cancer, and 74% have high cholesterol. Their average risk score is 1.62, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Goldfarb's median patient age at 58, with 95% women.

In 2024, Dr. Goldfarb wrote 93 Medicare Part D claims for 38 patients. 90% of them were for generic drugs. CMS names the drug for 32 of them, across 2 drugs with 11 or more claims each, at $894 in total drug cost. In 2023, CMS named 50 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 76 out of 100 for Dr. Goldfarb for performance year 2024, reported as part of a group. Dr. Goldfarb accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Goldfarb as offering telehealth.

Dmand AI links 48 papers to Dr. Goldfarb, published from 2006 to 2025. 2024 was the busiest year, with 5. The most frequent topics are Breast Neoplasms, Antineoplastic Agents and Alopecia. Dr. Goldfarb has published most often in Breast Cancer Res Treat. Dr. Goldfarb's most frequent co-authors are Mary L. Gemignani, MD, Clifford A. Hudis, MD and Shanu Modi, MD.

Dmand AI links Dr. Goldfarb to 6 clinical trials, 2 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Alopecia, Breast Neoplasms and Hypotrichosis. Memorial Sloan Kettering Cancer Center sponsors the most, 5.

CMS Open Payments shows 55 general payments to Dr. Goldfarb from 8 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 84% of the total. TerSera Therapeutics LLC paid the most, $48,357. It also lists 1 research payment totaling $38,439 in 2018.

Dr. Goldfarb graduated from SUNY Upstate Medical University in 2004.

Dr. Goldfarb is in network with 12 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.